Cell and gene therapy is quickly becoming one of the most closely watched areas in healthcare, and the numbers show why. The industry was valued at around USD 8.94 billion in 2025 and is expected to reach USD 10.44 billion in 2026. By 2035, it could climb to USD 47.18 billion, representing an impressive 18.1% annual growth.
What stands out to me is how quickly these therapies are moving beyond early-stage research. They are increasingly being developed to address some of the most difficult diseases, including cancer, inherited disorders, neurological conditions and autoimmune diseases. Instead of simply managing symptoms, many of these treatments aim to correct or replace damaged cells or faulty genetic material.
Cancer continues to attract the greatest attention, accounting for 39.48% of the industry in 2025. Cell therapy currently leads with a 64.78% share, supported by advances in stem cell and immune cell treatments. At the same time, gene therapy is gaining momentum, particularly with technologies such as CRISPR that are opening new possibilities for treating previously difficult or untreatable conditions.
I also see manufacturing becoming a critical part of the next phase. These therapies are complex and expensive to produce, and scaling them safely is not straightforward. While companies still rely heavily on their own facilities, contract development and manufacturing organizations are becoming increasingly important by providing specialized capabilities and additional production capacity.
North America remains the largest regional contributor, accounting for 49.88% in 2025. However, Asia Pacific is the region I would watch closely. With a projected annual growth rate of 20.7% through 2035, increasing investments in biotechnology, clinical research and advanced manufacturing are creating strong momentum across countries such as China, Japan and India.
Of course, challenges remain. Treatment costs are extremely high, manufacturing is complicated and access and reimbursement can be difficult, particularly in developing healthcare systems.
For me, the most important question now is not whether cell and gene therapy will grow. It is how quickly the industry can make these treatments more affordable, scalable and accessible to patients who need them.
Download Customized Sample: https://www.towardshealthcare.com/download-sample/5052
About Us
Healthcare WebWire is a part of Towards Healthcare Research & Consulting which is a global healthcare market research and consulting firm dedicated to helping businesses make informed decisions through reliable market intelligence and strategic insights. We serve pharmaceutical, biotechnology, medical device, AI in healthcare, cell and gene therapy, digital health, and life sciences organizations with in-depth market research, custom consulting, competitive analysis, and growth forecasts. Our team combines industry expertise with rigorous research to deliver clear, actionable insights that support market expansion, product strategy, investment decisions, and long-term business growth. From emerging innovations to established healthcare markets, we help organizations understand where the industry is today and where it’s headed tomorrow.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: Towards Healthcare Research & Consulting – Expert Consulting Solutions & Research Reports
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium